<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615249</url>
  </required_header>
  <id_info>
    <org_study_id>SP148MP201</org_study_id>
    <nct_id>NCT02615249</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Metal Panel Allergens: Dose Response Study</brief_title>
  <official_title>Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allerderm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allerderm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      48-hour application of metal allergen patches to test for potential allergic responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 48-hour application (approximate) of investigational allergen panels, excipient controls
      and corresponding reference allergens will be applied to the skin of human subjects to test
      for potential positive allergic responses. Test sites will be evaluated at 3-4, 7-8, 10-14
      and 19-23 days after application. Ascending allergen dosages will be randomized within each
      panel into three different configurations which will be randomly assigned to subjects as they
      enter the study. The investigators and subjects will be aware of the allergens and the patch
      test doses but will not be aware of the location of individual allergens within each panel.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal Test Allergen Dose</measure>
    <time_frame>21 days post patch application</time_frame>
    <description>The lowest concentration of each allergen eliciting a positive response in a minimum of 15 subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance</measure>
    <time_frame>21 days post patch application</time_frame>
    <description>Moderate to very good concordance, measured using Cohen's kappa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who exhibit Irritation</measure>
    <time_frame>2 days, 3-4 days, 7-8 days, 10-14 days and 19-23 days post application</time_frame>
    <description>The number of subjects who exhibit tape or polyester chip irritation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who experience Itching or Burning</measure>
    <time_frame>2 days post application</time_frame>
    <description>The number of subjects who report itching or burning sensations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who exhibit Positive Reactions</measure>
    <time_frame>3-4 days, 7-8 days, 10-14 days and 19-23 days post application</time_frame>
    <description>The number of subjects who exhibit positive allergic reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who exhibit negative, doubtful and irritant reactions</measure>
    <time_frame>3-4 days, 7-8 days, 10-14 days and 19-23 days post application</time_frame>
    <description>The number of subjects who exhibit non-positive (negative, doubtful or irritant) reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who exhibit late or persistent reactions</measure>
    <time_frame>7-8 days, 10-14 days and 19-23 days post application</time_frame>
    <description>The number of subjects who exhibit late or persistent reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 days, 3-4 days, 7-8 days, 10-14 days and 19-23 days post application</time_frame>
    <description>All adverse events will be captured</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Dermatitis, Eczematous</condition>
  <arm_group>
    <arm_group_label>Metal Allergen Epicutaneous Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of patch test allergens to test for positive allergic responses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Metal Allergen Epicutaneous Patch</intervention_name>
    <description>48 hour application of metal allergen patch to diagnose contact dermatitis</description>
    <arm_group_label>Metal Allergen Epicutaneous Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older.

          2. Past positive patch test result within the past 10 years (to one of the dilution
             series metals being tested on this study) or strong suspicion of metal contact allergy
             based on results of the Qualification Questionnaire.

          3. Unable to become pregnant or willing to use an acceptable method of contraception to
             prevent pregnancy if female of childbearing potential; (Inability to become pregnant
             includes all male subjects and female subjects who are postmenopausal for at least 1
             year, or surgically sterile- have had a hysterectomy, bilateral ovariectomy, uterine
             ablation or bilateral tubal ligation. Acceptable methods of contraception include: 1)
             systemic birth control; 2) double barrier method; 3) intrauterine device; 4)
             vasectomized partner; or 5) abstinence from sexual intercourse. Subject must agree to
             use acceptable contraception for the duration of the entire study.)

          4. Understands and signs the approved Informed Consent form which is consistent with all
             institutional, local and national regulations.

        Exclusion Criteria:

          1. Breastfeeding or pregnant (as determined by urine pregnancy test) or intending to
             become pregnant during the course of the study.

          2. Topical treatment with corticosteroids or other immunosuppressive agents on or near
             the test area during the 14 days prior to inclusion in this study.

          3. Systemic treatment with corticosteroids (equivalent to &gt; 10 mg prednisone) or other
             immunosuppressive agents during the 14 days prior to inclusion in this study. Inhaled
             treatments are permitted. NOTE: Steroidal nose or eye drops are permitted.

          4. Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to
             inclusion in this study.

          5. Acute dermatitis outbreak or dermatitis on or near the test area on the back.

          6. Conditions such as; fibromyalgia, chronic fatigue, depression, cognitive impairment,
             flu-like symptoms, diarrhea and/or headache without at least one of the symptoms
             related to metal exposure listed in Section 10.1 under physical examination

          7. Inability to comply with patch test study requirements including multiple return
             visits and activity restrictions (e.g., protecting test panels from excess moisture
             due to showering or vigorous activity).

          8. Participation in a clinical trial of an investigational drug, treatment or device
             during this study or 3 weeks prior to inclusion in this study.

          9. An opinion of the Investigator that deems the potential subject to be non-compliant,
             unable to return for study visits or complete the study as detailed in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia L Norris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health &amp; Science University, Portland USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Pacheco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health School of Medicine, Colorado USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Bircher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Pigatto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Rustemeyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians-Universität München, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maki Hosoki, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokushima University Graduate School, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Risa Tamagawa-Mineoka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto Prefectural University of Medicine, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akiko Yagami, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujita Health University School of Medicine, Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn M Shannon</last_name>
    <phone>602-225-0595</phone>
    <phone_ext>7208</phone_ext>
    <email>kshannon@smarthealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim M Sullivan</last_name>
    <phone>602-225-0595</phone>
    <phone_ext>7274</phone_ext>
    <email>sullivan@smarthealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Jewish Health, University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Pacheco, MD</last_name>
      <phone>303-398-1520</phone>
      <email>pachecok@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Karin Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universitat Munchen</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Thomas, MD</last_name>
      <phone>89 4400-45178</phone>
      <email>peter.thomas@med.uni-meunchen.de</email>
    </contact>
    <investigator>
      <last_name>Peter Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Milano</name>
      <address>
        <city>Milan</city>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Pigatto, MD</last_name>
      <phone>023314139</phone>
      <email>pigatto@pigattobersani.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Pigatto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujita Health University School of Medicine</name>
      <address>
        <city>Aichi</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akiko Yagami, Md, PhD</last_name>
      <email>ayagami@fujita-hu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Akiko Yagami, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Risa Tamagawa-Mineoka, MD</last_name>
      <phone>81 75-251-5586</phone>
      <email>risat@koto.kpu-m.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Risa Tamagawa-Mineoka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokushima University Graduate School</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maki Hosoki, DDS</last_name>
      <phone>81-88-633-7350</phone>
      <email>hosoki@tokushima-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Maki Hosoki, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Rustemeyer, MD, PhD</last_name>
      <phone>20.444.0111</phone>
      <email>trustemeyer@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Thomas Rustemeyer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel Allergology Unit</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Bircher, MD</last_name>
      <phone>61 265 5097</phone>
      <email>andreas.bircher@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Bircher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

